1. Home
  2. ZNTL vs ENTX Comparison

ZNTL vs ENTX Comparison

Compare ZNTL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$1.37

Market Cap

165.1M

Sector

Health Care

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$3.28

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZNTL
ENTX
Founded
2014
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.1M
147.4M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
ZNTL
ENTX
Price
$1.37
$3.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$7.44
★ $9.75
AVG Volume (30 Days)
★ 1.3M
237.8K
Earning Date
11-09-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.03
N/A
EPS
N/A
★ 0.33
Revenue
N/A
★ $42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$9.55
Revenue Growth
N/A
★ N/A
52 Week Low
$1.28
$0.91
52 Week High
$6.95
$4.20

Technical Indicators

Market Signals
Indicator
ZNTL
ENTX
Relative Strength Index (RSI) 22.22 58.73
Support Level N/A $2.71
Resistance Level $1.98 $3.52
Average True Range (ATR) 0.18 0.18
MACD -0.01 -0.00
Stochastic Oscillator 0.72 58.70

Price Performance

Historical Comparison
ZNTL
ENTX

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: